Sunday 18 October 2026
Export RLMD’s income statement to Excel — free account
Relmada Therapeutics, Inc.
RLMD Healthcare Biotechnology
In the quarter to June 2026, EPS grew 63.3% and free cash flow fell 50.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.10
0.10
−3.13%
Follow RLMD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
2.86 | 14.62 | 18.26 | 29.52 |
Net Debt/EBITDA |
1.34 | 4.57 | 12.02 | 14.50 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.67 | 0.73 | 0.79 | 0.74 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.20) | (0.37) | (0.17) | (0.09) | |
Cash per Share |
0.42 | 2.36 | 2.70 | 1.94 | |
Shareholders Equity per Share |
0.29 | 2.19 | 2.53 | 1.84 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.29 | 2.19 | 2.53 | 1.84 | |
Free Cash Flow |
(6.72) | (14.60) | (15.07) | (9.61) | |
Working Capital |
9.66 | 87.55 | 222.45 | 211.62 | |
Net Current Asset Value |
9.44 | 86.49 | 218.71 | 206.54 | |
| Other line items | |||||
Quick Ratio |
2.68 | 14.46 | 18.15 | 29.34 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.20) | (0.37) | (0.17) | (0.09) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
— | — | — | 0.05 | |
Average Payables |
1.90 | 2.85 | 3.50 | 1.89 | |
Average Assets |
35.30 | 69.91 | 131.52 | 120.09 | |
Average Common Equity |
28.55 | 61.02 | 120.59 | 111.25 |
Columns are period end dates